Kevzara Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to high rheumatoid arthritis prevalence, limitations of conventional dmards, clinical success of biologics, growing specialist rheumatology care, improved diagnosis rates.

The growth in the forecast period can be attributed to increasing autoimmune disease burden, expansion into additional inflammatory indications, rising biologic acceptance, improved access to specialty care, innovation in cytokine targeting. Major trends in the forecast period include rising adoption of il 6 inhibitors, growth in biologic ra treatments, expansion of targeted anti inflammatory therapies, preference for injectable biologics, focus on long term disease control.

The growing prevalence of rheumatoid arthritis (RA) is expected to significantly contribute to the expansion of the Kevzara market in the future. Rheumatoid arthritis (RA) is a chronic autoimmune condition that primarily affects the joints, leading to inflammation, pain, swelling, and stiffness. The rising prevalence of RA is influenced by various factors, including genetic predisposition, environmental triggers, hormonal changes, and immune system dysfunction. Kevzara helps manage RA symptoms by specifically targeting and blocking IL-6, a protein that promotes inflammation. By doing so, it helps reduce inflammation, improve joint health, and enhance the overall quality of life for those living with the condition. For example, in February 2024, the Arthritis Australia, a government agency based in Australia, projected that the number of Australians with arthritis will rise from 4.11 million in 2025 to 5.39 million by 2040. During the same period, osteoarthritis cases are expected to increase from 2.35 million to 3.11 million, while the number of individuals with rheumatoid arthritis is forecast to reach 748,721 by 2040. As a result, the growing prevalence of rheumatoid arthritis (RA) is driving the growth of the Kevzara market.

The rise in healthcare expenditure is expected to further drive the growth of the Kevzara market. Healthcare expenditure refers to the total financial resources allocated for healthcare services and products within a country or region. Several factors contribute to the increase in healthcare expenditure, including an aging population, advancements in medical technology, rising healthcare costs, a focus on preventive care, and the expansion of health insurance coverage. As an expensive biologic treatment for rheumatoid arthritis and other inflammatory conditions, Kevzara requires ongoing administration, leading to long-term treatment costs. Its high price contributes significantly to overall healthcare expenditure for both patients and healthcare systems. For example, in May 2024, a report from the Office for National Statistics, a UK government agency, showed that total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a growth of 0.9% in 2022. Consequently, the rise in healthcare expenditure is contributing to the growth of the Kevzara market.

A key trend in the Kevzara market is the development of advanced products, such as interleukin-6 (IL-6) receptor blocker medications, to expand the therapeutic uses for inflammatory disorders. An IL-6 receptor blocker is a biological drug that targets and blocks IL-6, a protein responsible for inflammation. This helps reduce inflammation and treat conditions like rheumatoid arthritis. For example, in February 2023, Regeneron Pharmaceuticals Inc., a U.S.-based biotechnology company, and Sanofi, a France-based healthcare company, announced that the U.S. Food and Drug Administration (FDA) approved Kevzara (sarilumab) for treating polymyalgia rheumatica (PMR), an inflammatory rheumatic disorder in adults who have not responded well to corticosteroids or cannot tolerate a reduction in their corticosteroid dosage. Kevzara, as an IL-6 receptor blocker, helps reduce inflammation and disease activity. Administered through subcutaneous injection, it provides an alternative to long-term steroid use. The medication has shown significant efficacy in achieving sustained remission in PMR patients and reducing their dependence on corticosteroids.

Major companies operating in the kevzara market are Sanofi S.A., Regeneron Pharmaceuticals Inc.

North America was the largest region in the kevzara market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kevzara market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the kevzara market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the kevzara market by increasing costs of biologic manufacturing inputs and temperature controlled distribution. Rheumatology treatment segments in north america and europe are most affected due to dependence on imported monoclonal antibodies. These tariffs may influence therapy affordability. At the same time, tariffs are encouraging regional biologics production and strengthening domestic manufacturing capabilities for inflammatory disease treatments.

The kevzara market research report is one of a series of new reports that provides kevzara market statistics, including kevzara industry global market size, regional shares, competitors with a kevzara market share, detailed kevzara market segments, market trends and opportunities, and any further data you may need to thrive in the kevzara industry. This kevzara market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Kevzara is a prescription biologic medication classified as a monoclonal antibody, designed for the treatment of moderate to severe rheumatoid arthritis (RA) in adults. It functions by targeting and inhibiting interleukin-6 (IL-6), a protein involved in the inflammatory process. By blocking IL-6 receptors, Kevzara helps reduce inflammation and relieve symptoms associated with RA. In addition to RA, Kevzara may be prescribed for other inflammatory conditions, as determined by healthcare providers.

The primary formulations of Kevzara include injectable formulations and autoinjectors. Injectable formulations administer the biologic therapy directly into the bloodstream through injection, ensuring a controlled release and effective treatment for chronic conditions like rheumatoid arthritis. Kevzara is used for a range of indications, such as the treatment of moderate to severe rheumatoid arthritis, giant cell arteritis, and others. It is applicable to various patient groups, including pediatric, adult, and geriatric patients. The drug is distributed through multiple channels, including direct sales, wholesalers, retail pharmacies, and online pharmacies. It is utilized by a variety of healthcare settings, such as hospitals, specialty clinics, outpatient treatment centers, and home healthcare providers.

The kevzara market consists of sales of subcutaneous injections, pre-filled syringes, and pre-filled pens. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.